Abstract: An automated manufacturing control system is proposed to greatly reduce the human interaction relative to the data transfer, physical verification and process control associated with the movement of components, tooling and operators in a manufacturing system. This is achieved by the use of data carriers which are attached to the object(s) to be traced. These data carriers (12) can store all the relevant identification, material and production data required by the various elements, e.g. stations, of the manufacturing system. Various readers, integrated with controllers and application software, are located at strategic points of the production area, including production machines and storage areas, to enable automatic data transfer and physical verification that the right material is at the right place at the right time, using the right tooling.

Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.

Abstract: This invention is directed to a modified form of a prodrug. A typical form of prodrug according to the invention comprises a bulky group, a spacer, a structure that can be cleaved at or near the target cells and a therapeutic agent or a marker, whereby the spacer allows or facilitates the cleavage of the cleavable structure.

Abstract: An automated manufacturing control system is proposed to greatly reduce the human interaction relative to the data transfer, physical verification and process control associated with the movement of components, tooling and operators in a manufacturing system. This is achieved by the use of data carriers which are attached to the object(s) to be traced. These data carriers (12) can store all the relevant identification, material and production data required by the various elements, e.g. stations, of the manufacturing system. Various readers, integrated with controllers and application software, are located at strategic points of the production area, including production machines and storage areas, to enable automatic data transfer and physical verification that the right material is at the right place at the right time, using the right tooling.

Abstract: A closed loop location detection system for use in monitoring simultaneously the presence or absence of objects in at least two locations, comprises at least one detectable element per location and adapted to be associated with a respective object to be monitored, and at least one detecting device adapted to detect the detectable elements of the objects and so determine whether objects are present in, or absent form, all of the locations being monitored. Means are provided for causing an object to be fed to a location determined to be devoid of objects by the detecting device. Typically, the closed loop location detection system uses RFID technology, e.g. the detection device comprises at least one antenna and the detectable element comprising at least one RF tag. There may be provided one such antenna for each location to be monitored, whereby for a given location, a respective antenna detects the presence or absence of a respective tag thereby determining whether an object is present in this given location.

Abstract: An automated manufacturing control system is proposed to greatly reduce the human interaction relative to the data transfer, physical verification and process control associated with the movement of components, tooling and operators in a manufacturing system. This is achieved by the use of data carriers which are attached to the object(s) to be traced. These data carriers (12) can store all the relevant identification, material and production data to required by the various elements, e.g. stations, of the manufacturing system. Various readers, integrated with controllers and application software, are located at strategic points of the production area, including production machines and storage areas, to enable automatic data transfer and physical verification that the right material is at the right place at the right time, using the right tooling.

Abstract: The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of: a) halogenating a compound of formula (II), resulting in compound of formula (IIa), b) reacting a compound of formula (IIa) at its 14 position with the thiol moiety of a peptide of formula (III), optionally in the presence of a suitable linker, to obtain said compound of formula (I), wherein R1 represents OH, NH2 or NH-peptide; R2 represents H or —CO-peptide; R3 represents OCH3, OH or H; R4 represents H, or COCF3; R5 represents OH, O-tetrahydropyranyl or H; R6 represents OH or H; R7 represents H, OH, OCO(CH2)3CH3 or OCOCH(OC2H5)2; R8 represents OH or H; R9 represents OH or H; R10 represents a halogen and L is an optional suitable linker arm.

Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.

Abstract: Compounds are disclosed with the general formula A-B, which in the vicinity of tumor cells result in a positively charged moiety B and an uncharged or negatively charged moiety A. Moiety B is able to induce blood clotting by interacting with negatively charged heparin-like substances lining vascular endothelia and the positive charge is reversibly masked by the uncharged or negatively charged moiety A in order to prevent unspecific disseminated blood coagulation and toxicity. Moiety B is either a covalent assembly of positively charged chemical groups or a positively charged molecule, which in aqueous solutions forms non-covalent polycations due to its propensity to form intermolecular aggregates. Pharmaceutical compositions including the compound and a pharmaceutically acceptable adjuvant or excipient are also disclosed. The disclosed compounds are useful in medicine, in particular for the manufacture of a medicament and its use for the treatment of a subject.

Abstract: The invention is directed to novel prodrug compounds, compositions comprising the prodrug compounds, methods of making the prodrug compounds and methods of using the prodrug compounds. The prodrug compounds comprise a biologically active entity linked to a masking moiety via a linking moiety. The prodrug compounds are selectively activated at or near target cells and display lower toxicity and possibly a longer in vivo or serum half-life than the corresponding naked biologically active entity.

Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.

Abstract: An automated manufacturing control system is proposed to greatly reduce the human interaction relative to the data transfer, physical verification and process control associated with the movement of components, tooling and operators in a manufacturing system. This is achieved by the use of data carriers which are attached to the object(s) to be traced. These data carriers (12) can store all the relevant identification, material and production data required by the various elements, e.g. stations, of the manufacturing system. Various readers, integrated with controllers and application software, are located at strategic points of the production area, including production machines and storage areas, to enable automatic data transfer and physical verification that the right material is at the right place at the right time, using the right tooling.

Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.

Abstract: An antenna of the type comprising a set of distributor circuits made by symmetrical strip line circuit technology, distributing microwave energy to M radiating elements. The symmetrical strip line distribution circuits are placed so that they have at least one portion of their ground planes in common, thus reducing the bulk and weight of the antenna.